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Abstract
Cancer survivorship rates have drastically increased due to improved efficacy of
oncologic treatments. Consequently, clinical concerns have shifted from solely focusing
on survival to quality of life, with fertility preservation as an important consideration.
Among fertility preservation strategies for female patients, ovarian tissue cryopreserva-
tion and subsequent reimplantation has been the only clinical option available to cancer
survivors with cryopreserved tissue. However, follicle atresia after transplantation and
risk of reintroducing malignant cells have prevented this procedure from becoming
widely adopted in clinics. Herein, we investigated the encapsulation of ovarian follicles
in alginate hydrogels that isolate the graft from the host, yet allows for maturation after
transplantation at a heterotopic (i.e., subcutaneous) site, a process we termed in vivo
follicle maturation. Survival of multiple follicle populations was confirmed via histology,
with the notable development of the antral follicles. Collected oocytes (63%) exhibited
polar body extrusion and were fertilized by intracytoplasmic sperm injection and
standard in vitro fertilization procedures. Successfully fertilized oocytes developed to
the pronucleus (14%), two‐cell (36%), and four‐cell (7%) stages. Furthermore, ovarian
follicles cotransplanted with metastatic breast cancer cells within the hydrogels allowed
for retrieval of the follicles, and no mice developed tumors after removal of the implant,
confirming that the hydrogel prevented seeding of disease within the host. Collectively,
these findings demonstrate a viable option for safe use of potentially cancer‐laden
ovarian donor tissue for in vivo follicle maturation within a retrievable hydrogel and
subsequent oocyte collection. Ultimately, this technology may provide novel options to
preserve fertility for young female patients with cancer.
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1 | INTRODUCTION
Advances in chemo‐ and radiotherapy have significantly improved
cancer survivorship rates worldwide. As of 2016, the American Cancer
Society (ACS) estimates that more than 15 million individuals in the
United States are currently in remission. By 2024, ACS projects this
number will increase to more than 19 million, of which 9 million will be
female (American Cancer Society, 2014; 2017). In particular, the 5‐year
survival rate for pediatric patients (0‐ to 14‐year age group) has
improved to 87% during the 2008–2012 period (Wallace, Kelsey, &
Biotechnology and Bioengineering. 2018;115:2075–2086. wileyonlinelibrary.com/journal/bit © 2018 Wiley Periodicals, Inc. | 2075
Anderson, 2016). Given these estimates, clinical concerns have shifted
to include fertility preservation after treatment.
Alkylating chemotherapy or irradiation to the pelvis or abdomen
in female patients can be gonadotoxic and cause irreversible damage
to the ovaries, reducing the patient’s ability to conceive successfully
by 50% (Salama & Woodruff, 2015; Shea, Woodruff, & Shikanov,
2014). In cases where doses of abdominal radiation of 20–30 Gy are
used, the risk of adverse pregnancy outcomes can be as high as 90%
(Kim, Kim, Lee, & Woodruff, 2016; Wallace, Shalet, Hendry, Morris‐
Jones, & Gattamaneni, 1989; Wo & Viswanathan, 2009). Currently
available options to preserve fertility before treatment include
embryo cryopreservation, oocyte cryopreservation, and ovarian
tissue cryopreservation, though embryo and oocyte cryopreservation
may not be applicable to pediatric patients.
The transplantation of cryopreserved ovarian tissue is the only
clinical option available to restore fertility using cryopreserved tissue
and has resulted in 60 live births reported to date (Donnez & Dolmans,
2015). This procedure does not require hormonal stimulation or a sperm
donor, preserves ovarian follicles at all stages of maturation, including
primary and primordial follicles, and can be applied to prepubertal girls
(Kim et al., 2016; Kondapalli & Ginsberg, 2012; Meirow, Ra, & Biderman,
2014). However, this method is still considered experimental and is
associated with several challenges related to reimplantation that prevent
it from becoming the gold standard for fertility preservation. These
challenges include ischemic injury early after transplantation due to
insufficient tissue revascularization, which significantly reduces the
ovarian follicle pool, follicular atresia, and risk of reseeding malignant
cancer cells (Demeestere, Simon, Emiliani, Delbaere, & Englert, 2009;
Donnez, Squifflet, & Dolmans, 2009; Salama & Woodruff, 2015). In
particular, the reintroduction of malignant disease remains a primary
concern as 12.4% of patients died due to recurrence after reimplantation
of cryopreserved ovarian tissue according to a 12‐year study (Imbert
et al., 2014). Thus, the presence of cancer cells in cryopreserved ovarian
tissue (Abir et al., 2014; Dolmans, Luyckx, Donnez, Andersen, & Greve,
2013; Rosendahl, Greve, & Andersen, 2013) has motivated strategies
such as follicle isolation and transplantation as a means to reduce or
remove the cancer cell population (Kniazeva et al., 2015).
Hydrogels have been used for the transplantation of ovarian tissue or
isolated follicles as a means to enhance efficacy. The three‐dimensional
architecture of the hydrogel physically supports the follicles, maintains
oocyte–somatic cell connections, and permits expansion of early‐stage
follicles (Shea et al., 2014). In particular, fibrin hydrogels have been used
for ovarian follicle transplantation to facilitate the interaction of the
transplant with the host. Transplantation of fibrin‐encapsulated follicles
has promoted their survival after transplantation, enabled growth and
maturation in vivo, and restored endocrine function in the ovariecto-
mized mice (Kniazeva et al., 2015; Luyckx et al., 2014; Smith et al., 2014).
Restoration of endocrine function is particularly important and necessary
for successful clinical pregnancies (Donnez et al., 2013; Oktay et al.,
2001). Fibrin hydrogels modified with vascular endothelial growth factor
(VEGF) and transplanted into the orthotropic site of ovarian bursa
have improved encapsulated murine follicle function and resulted in live
births via natural pregnancy (Kniazeva et al., 2015; Shikanov, Ph et al.,
2011; Smith et al., 2014). There are at least two significant challenges
with these approaches however: (i) the live births required a relatively
large number of transplanted follicles that may be difficult to obtain in a
clinical setting from human tissue, and (ii) the degradation of the fibrin
hydrogel and integration of the graft with the host tissue could allow for
dissemination of residual cancer cells.
In this report, we investigated a strategy for transplantation of
ovarian follicles within nondegradable alginate hydrogels to allow in
vivo follicle maturation, with subsequent retrieval of the graft to obtain
mature oocytes for in vitro fertilization (IVF). Alginate hydrogels have
been used for encapsulation to provide support for culture and
maturation of mouse follicles (Filatov, Khramova, & Semenova, 2014;
Hornick, Duncan, Shea, & Woodruff, 2012; Hornick, Duncan, Shea, &
Woodruff, 2013; Telfer & Zelinski, 2013; Xiao, Duncan et al., 2015; Xu,
Banc, Woodruff, & Shea, 2009) and human follicles (Laronda et al.,
2014; Xiao, Zhang et al., 2015) in vitro. Oocytes can be retrieved from
alginate‐encapsulated murine follicles for IVF and subsequently
implanted to produce healthy offspring (Xu, Kreeger, Shea, & Woodruff,
2006). Here, we proposed to apply the alginate hydrogels for in vivo
maturation at a subcutaneous site, with the hydrogels providing
support for follicle growth, while also presenting an effective barrier
that limits integration with the host tissue and potentially facilitates
implant retrieval. After encapsulation and transplantation, hydrogels
were extracted and carefully dissected to collect oocytes for in vitro
maturation (IVM) and subsequent fertilization by intracytoplasmic
injection and standard IVF. Furthermore, we assessed the ability of
cancer cells encapsulated together with the follicles to initiate tumor
development within the transplant recipient. We were able to
demonstrate that retrievable hydrogels used for follicle maturation
provide a unique opportunity to maintain follicle architecture and allow
maturation within the in vivo environment, while eliminating the risks
associated with potentially cancer‐laden ovarian tissue.
2 | MATERIALS AND METHODS
2.1 | Follicle isolation and hydrogel fabrication
Ovaries were extracted from 12‐day‐old C57BL/6j x CBA/Ca female
mice (Harlan Laboratories, Indianapolis, IN) and mechanically dis-
sected using insulin syringe needles (1cc, 28G1/2) (BD Biosciences,
Franklin Lakes, NJ). The tissue is dissected as a means to collect
follicles primarily and reduce the population of stromal cells. Although
stromal cells are present, their quantity has been reduced. The
resulting ovarian fragments, approximately 300 µm in diameter, were
allowed to aggregate in a 0.6‐ml Eppendorf tube in Leibovitz’s L‐15
media (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS; Gibco) and 1% PenStrep (Sigma‐Aldrich, St. Louis, MO).
Follicle isolation was performed on a heated stage at 37°C in a
sterilized hood to prevent contamination. Either three, two, or one
ovary was dissected and incorporated into each of the gels, which
correspond to a mixture of primordial, primary, and secondary follicles
with approximately 1,100, 730, or 360 follicles, respectively, based on
follicle quantification from native 12‐day‐old ovaries. To form alginate
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hydrogels, the supernatant was removed until only the follicle
aggregate remained. Next, 7 µl of 0.5% alginate (NovaMatrix, Sandvika,
Norway) mixed with sterile phosphate buffered saline (PBS−/–)
(Perkin Elmer, Waltham, MA) was slowly added to the tube without
disturbing the follicles, followed by 50 µl of thrombin/Ca2+ (Sigma‐
Aldrich, St. Louis, MO), and the resulting mixture was allowed to
crosslink for 3min. The thrombin/Ca2+ solution was created by
combining 50 IU/ml thrombin with 40mM CaCl2. Hydrogels were
approximately 3mm in diameter and kept in L‐15 media before
transplantation.
2.2 | Ovariectomy and transplantation
Hydrogels were transplanted into C57BL/6j x CBA/Ca adult 6‐ to
7‐week‐old female mice after ovariectomy, either into the ovarian
bursa or subcutaneously in the dorsal region. Mice were anesthetized
with intraperitoneal injection of 100mg/kg of ketamine and 15mg/kg
of xylazine. Hydrogels were implanted into the bursa according to a
previous report (Kniazeva et al., 2015). For subcutaneous implants, a
small incision was made on the back to form a pocket, hydrogels
were inserted, and then the incision was closed using a 5‐0 vicryl
suture (Ethicon, Somerville, NJ). Sterile surgical procedures, post-
operative procedures, and daily care were performed according to
protocols approved by the Northwestern University Institutional
Animal Care and Use Committee.
2.3 | Retrieval and analysis of hydrogel transplants
After 7 days, mice were euthanized, and ovarian bursae or subcutaneous
implants were retrieved for histological analysis. On removal, samples
were fixed in 4% paraformaldehyde, dehydrated in 70% ethanol,
paraffin‐embedded, serial‐sectioned, and stained with hematoxylin and
eosin (H&E). Follicle counts were performed by an experienced
researcher blinded to experimental conditions. Follicles were quantified
according to the following classification scheme: primordial follicles
contained four to six squamous granulosa cells, primary follicles were
enclosed by and contained a mix of squamous and cuboidal cells,
secondary follicles contained two layers of cuboidal granulosa cells,
multilayered secondary follicles contained more than two layers of
cuboidal layers with no presence of a cavity (i.e., corpus luteum), and
antral follicles were identified by the presence of an oocyte surrounded
by several layers of cuboidal cells and a defined corpus luteum.
2.4 | Oocyte collection, IVM assay,
and immunofluorescence
Hydrogels were explanted 7 days after transplant in the bursa or
subcutaneous site and placed in L‐15 medium. Hydrogel samples were
mechanically dissected on a heated‐stage microscope using insulin
syringe needles (1cc, 28G1/2) to obtain antral follicles. Antral follicles
were carefully punctured to release oocytes into the surrounding
media. Only oocytes with a visible germinal vesicle, and thus arrested at
prophase I, were transferred to IVM media alpha minimum essential
medium (α‐MEM) with 10% FBS, 1.5 IU/ml human chorionic gonado-
tropin, and 10 ng/ml epidermal growth factor (BD Biosciences, Franklin
Lakes, NJ). Oocytes were incubated for 16 hr at 37°C in 5% CO2 and
then imaged to confirm MII status, denoted by polar body extrusion. A
subset of metaphase II (MII) oocytes derived from hydrogel samples
from the bursa or subcutaneous site was immunofluorescently stained
and imaged with a confocal microscope (Leica Microsystem) using
previously cited methods (Xiao, Zhang et al., 2015) to assess the
morphology of the meiotic spindle, a marker of egg quality.
2.5 | IVF and embryo development
Oocytes derived from subcutaneously transplanted hydrogel samples
containing 1,100 follicles were used for IVF and embryo development
studies. After confirmation of MII status via polar body extrusion
after IVM, oocytes were fertilized with sperm collected from the
epididymis of 8‐ to 10‐week‐old C57BL/6j x CBA/Ca male mice. Isolated
epididymides were placed in a 1.5‐ml Eppendorf tube with 1ml of
human tubular fluid (HTF) medium supplemented with 0.4% of bovine
serum albumin. Sperm were incubated for 30min at 37°C, and the
supernatant layer containing healthy and motile sperm was collected.
Sperm was either injected directly into oocytes using intracytoplasmic
sperm injection (ICSI) or placed in the HTF medium with oocytes using
the standard IVF procedures. For ICSI, MII oocytes were placed in 50 µl
drops of EmbryoMax KSOM Medium (1× with ½ amino acids; Millipore,
Burlington, MA) on a heated microscope stage (Nikon Eclipse TE300),
and sperm were microinjected using a Piezo‐drill tip (Eppendorf,
Hamburg, Germany) containing Fluorinert FC770 (Sigma‐Aldrich, St.
Louis, MO) to generate a pulse sufficient to penetrate the zona pellucida.
After sperm injection, MII oocytes were left in 50 µl of KSOM medium
submersed in Embryo Culture Oil (Irvine Scientific, Santa Ana, CA) and
monitored for up to 96 hr to evaluate embryo outcomes. Standard IVF
was also used to fertilize MII oocytes. In brief, the zona pellucida was
denuded using acetic acid and transferred to HTF medium. A low sperm
concentration of 5,000 sperm total was added to 1ml of HTF with MII
oocytes for 24 hr and then transferred to a fresh 50 µl of KSOMmedium
without sperm. MII oocytes were then cultured for another 72 hr for a
total of 96 hr to assess embryo outcomes after fertilization.
2.6 | Cancer‐cell‐laden hydrogel transplants,
in vivo luminescence imaging, and organ histology
Alginate hydrogel (7 µl, 0.5%) containing approximately 200 triple
negative breast cancer cell line (MDA‐MB‐231 BR) cells expressing
luciferase and approximately 360 ovarian follicles from a cluster of
differentiation-1 (CD‐1) female mouse donor was transplanted into
the dorsal subcutaneous site of non-obese diabetic-severe com-
bined immunodeficiency (NOD-SCID) gamma (NSG) mice. At Day 7,
mice were injected (150 mg/kg) with D‐luciferin firefly (20 mg/ml in
sterile PBS) and imaged 10 min after injection on an in vivo imaging
system (IVIS; Perkin Elmer Xenogen IVIS Spectrum Bioluminescence
System) to confirm the presence of cancer cells in the gel. Hydrogel
implants were removed after imaging, and mice were monitored for
3 weeks after removal of the gel, at which time the mice were
imaged again to determine if cancer cells were present at the
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subcutaneous transplant site. Liver and lungs were excised from all
recipients within a week after the last imaging time point, fixed in
4% paraformaldehyde (PFA), paraffin‐embedded, and stained with
H&E to assess if metastasis occurred from the initial transplant site.
3 | RESULTS
3.1 | In vivo follicle transplantation within
hydrogels and histological analysis
Hydrogel encapsulation was evaluated for its ability to support
follicle survival and development in vivo. Specifically, alginate was
chosen to encapsulate mechanically isolated follicle aggregates
and subsequently transplanted subcutaneously in the dorsal
region (a heterotopic site) of ovariectomized female recipient
mice, with transplantation into the ovarian bursa (an orthotopic
site) used as a control based on the previous reports of follicle
maturation and consequent successful live births. A range of
follicle quantities (1,100, 730, or 360) was encapsulated within
hydrogels, and surviving populations of follicles at all develop-
mental stages were observed in grafts extracted from both the
subcutaneous and bursa transplant sites (Figure 1a–d). Notably,
antral follicles containing oocytes were identified within the
hydrogel explants (Figure 1a,c), which were not initially present
within the encapsulated follicle populations and thus developed
from this original pool (Supporting Information Figure 1a–c).
Quantification of follicle populations from removed grafts
implanted subcutaneously indicated that a majority of the follicles
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F IGURE 1 Follicle survival and growth in hydrogel explants 7 days after transplantation in subcutaneous and bursa sites. Antral,
multilayered secondary, and secondary follicles were observed in extracted ovarian grafts from the subcutaneous and bursa sites (a, b and c, d).
In panel (a), surrounding alginate material served to maintain the separation of host tissue from follicles transplanted subcutaneously.
A representative antral follicle is denoted with an asterisk (*) in panels (a) and (c). Large numbers of primordial and primary follicles were
identified in all extracted hydrogels and denoted with a single (*) or double asterisk (**), respectively, in panels (b) and (d). Hydrogel implant in
panels (a)-(b) and (c)-(d) contained approximately 360 and 1,100 follicles, respectively. Similar results were observed for alginate hydrogels with
follicle populations of approximately 730 ovarian follicles at both sites. Scale bar: 100 μm [Color figure can be viewed at wileyonlinelibrary.com]
were primordial, with antral follicles observed in all conditions
(Figure 2a,b). For the subcutaneous grafts, the greatest number of
transplanted follicles resulted in the smallest percentage of surviving
follicles (Figure 2c). Transplantation of the smallest initial follicle
numbers resulted in the greatest survival percentage (≈76%).
Relative to the transplanted population, the number and percentage
of primordial follicles had decreased, with a corresponding increase
in the number and percentage of primary and secondary follicles,
suggesting follicle maturation within the bead during the time of
transplantation. The number of recovered follicles from the bursa
significantly decreased, and recovery from this site was inefficient
relative to the subcutaneous site. Transplantation of the smallest
initial numbers of follicles (i.e., 360 follicles) in the bursa had the
greatest survival percentage of 20%. As with the subcutaneous site,
the largest follicle populations were in primordial and secondary
stages. Finally, despite the lower resulting number of primordial and
secondary follicles, the number of antral stage follicles was similar to
the subcutaneous site.
3.2 | Hydrogel retrieval, oocyte collection,
and IVM studies
On retrieval, the subcutaneously transplanted hydrogels were used
to obtain antral follicles for the investigation of oocyte quality.
Alginate hydrogels retained their integrity on extraction and allowed
for easy follicle dissection (Figure 3a). For transplantation of the
largest initial follicle numbers, a total of 54 oocytes in the germinal
vesicle stage were retrieved, transferred to IVM media, and imaged
after a 16‐hr incubation period. Polar body extrusion was evident
in 34 oocytes (MII stage), which corresponds to a 63% MII rate
(Figure 3b,c). For transplants with the reduced number of follicles
transplanted, the oocytes had an MII rate of 55% (730 follicles
transplanted) and 46% (360 follicles transplanted). Importantly, the
MII rate was comparable between all three conditions, suggesting
that MII oocytes can be achieved with modest numbers of follicles
transplanted. Finally, normal spindle morphology was confirmed in
MII oocytes derived from alginate hydrogels initially loaded with
1,100 follicles (Figure 3d).
Germinal vesicle oocytes isolated from antral follicles trans-
planted into the bursa (Figure 4a) underwent IVM to produce an MII
rate of 20% (Figure 4b,c). Normal spindle morphology indicative of
oocyte quality was confirmed in MII eggs after IVM (Figure 4d).
Intact hydrogel retrieval from the bursa was more challenging than
from the subcutaneous space, which resulted in a lower yield.
Subsequent studies thus focused only on the subcutaneous site.
3.3 | Fertilization and embryonic development
The fertilization competency of the MII stage oocytes that were
obtained from the subcutaneously transplanted follicles were
subsequently investigated (Figure 5a). ICSI was used to fertilize
eggs, and embryo development was monitored for 96 hr after ICSI.
Of the 14 MII eggs that were successfully injected with sperm,
oocytes progressed to the pronucleus (14%), two‐cell (36%), and
four‐cell (7%) stages, whereas 40% of oocytes remained in MII arrest
(Figure 5b). Embryos fertilized via standard IVF progressed to the
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F IGURE 2 Percentage of follicle populations recovered from alginate hydrogel explants 7 days after transplant. Follicle populations
(primordial, primary, secondary, multilayered secondary, and antral) were quantified and displayed as a percentage of recovered follicles for
the 1,100‐, 730‐, and 360‐follicle implant conditions for the (a) subcutaneous (n = 3/follicle condition) and (b) bursa transplant sites (n = 4
for 1,100‐follicle and 730‐follicle condition, n = 3 for 360‐follicle condition). (c) Percentage of surviving follicles for the subcutaneous and
bursa transplant sites (± standard error of the mean)
pronucleus (20%) and two‐cell (40%) stages, whereas 40% of oocytes
remained in MII arrest (Figure 5c).
3.4 | Cancer‐laden hydrogel implants and in vivo
imaging
We next investigated the safety of this strategy by the addition of cancer
cells to the isolated follicles followed by their encapsulation and
transplantation. We hypothesized that the alginate hydrogel, which
prevents direct contact between the host and transplanted tissue, would
prevent the escape of cancer cells into the host tissue after
transplantation and during retrieval. Approximately 200 MDA‐MD‐231
BR cells expressing luciferase were encapsulated with approximately
360 ovarian follicles into alginate hydrogels and implanted subcuta-
neously into NSG mice. The delivery of 20 cells or more of the MDA‐
MD‐231 BR cells can lead to tumor formation in this model (Supporting
Information Figure 2a–d). In vivo bioluminescence imaging of the follicle/
cancer cell transplants at Day 7 confirmed the presence of cancer cells
within the implant (n =4), whereas a luminescence signal was not
detected in the follicle transplant‐only control group (n = 4; Figure 6a).
Hydrogels were then removed, and recipient mice were imaged again at
3 weeks after removal of the gel, with no detection of a bioluminescence
signal (Figure 6b). The lung and liver were removed within 1 week after
imaging and analyzed for metastases. Histology confirmed no metastatic
lesions in the lungs or liver compared with control organs in all recipient
mice, supporting the safety of this strategy (Figure 7a–d).
4 | DISCUSSION
This report presents a strategy for in vivo maturation of ovarian
follicles, which involved the isolation and encapsulation of follicles into
alginate hydrogels, transplantation into the subcutaneous space, and
their subsequent retrieval for recovery of antral follicles containing
mature oocytes. Alginate hydrogels have been widely used for in vitro
follicle culture (Brito et al., 2014; Camboni et al., 2013; Hornick et al.,
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F IGURE 3 Egg retrieval from encapsulated follicles in alginate hydrogels in subcutaneous site 7 days after transplant and their meiotic
maturation in vitro. (a) Follicles were easily identified in explanted hydrogels. (b) MII oocytes were confirmed via polar body extrusion (indicated
with black arrows). (c) Egg retrieval and MII status from the subcutaneous site. Of the GV oocytes collected from antral follicles in Day 7
explants with 1,100 ovarian follicles, 34 of 54 oocytes were MII after in vitro maturation (63% MII rate) from three trials. Oocytes collected
from Day 7 explants with 730 or 360 ovarian follicles resulted in an MII rate of 55% (6 MII oocytes/11 GV oocytes) and 46% (10 MII oocytes/22
GV oocytes), respectively (d) Normal spindle morphology (indicated by an arrow) was also confirmed in subcutaneously matured oocytes. Image
(d) depicts an oocyte obtained from an explant containing ovarian follicles from three ovaries. Scale bar: 100 μm (a, b). DAPI, 4ʹ,6-diamidino-
2-phenylindole; GV, germinal vesicle; MII, metaphase II [Color figure can be viewed at wileyonlinelibrary.com]
2012; Kniazeva et al., 2015; Kreeger, Deck, Woodruff, & Shea, 2006;
Laronda et al., 2014; West, Xu, Woodruff, & Shea, 2007; Xiao, Duncan
et al., 2015; Xiao, Zhang et al., 2015; Xu et al., 2009) and for cell
transplantation, such as encapsulated islets as a therapy for type 1
diabetes (Köllmer, Appel, Somo, & Brey, 2015; Ludwig et al., 2013; Qi,
2014; Scharp & Marchetti, 2013) and also ovarian follicles (David et al.,
2017; Vanacker, Dolmans, Luyckx, Donnez, & Amorim, 2014). Islets
are encapsulated within the hydrogel for isolation from the host
over several months, yet the islets are able to survive, sense blood
glucose levels, and secrete insulin that can distribute systemically to
normalize blood glucose levels. Herein, we used alginate hydrogels for
the transplantation of ovarian follicles with the objectives of sensing
the hormonal milieu that can drive follicle development and matura-
tion, yet also isolation of the follicles from the host to facilitate their
recovery on maturation and prevent the reseeding of cancer cells that
may be present within the donor tissue. For the studies herein, the
hydrogel was loaded primarily with early‐stage follicles (i.e., primordial
and primary follicles); the extracted hydrogel grafts contained follicles
at all developmental stages, with a notable number of antral follicles.
Of the MII oocytes identified after IVM from matured antral follicles,
more than a third progressed to the two‐cell embryo stage after either
ICSI or standard IVF, which is consistent with results found in the
previous fertilization studies (Ellenbogen, Shavit, & Shalom‐Paz, 2014;
Jin, Lei, Shikanov, Shea, & Woodruff, 2010; Walls, Junk, Ryan, & Hart,
2018). These findings confirm the feasibility for use and utility of
alginate hydrogels for in vivo maturation of ovarian follicles to obtain
meiotically competent oocytes.
Subcutaneous implantation of the hydrogel grafts was initially
investigated based on the potential for relatively easy implantation and
retrieval, yet the number of follicles recovered was significantly
enhanced relative to implantation in the bursa. The bursa site was
used as a control for comparison at the subcutaneous site based on the
previous reports of live births achieved with transplantation of ovarian
tissue and ovarian follicles (Kniazeva et al., 2015; Shikanov, Zhang et al.,
2011). Although antral follicles could be recovered from alginate
hydrogels implanted into the bursa, and oocyte maturation produced
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F IGURE 4 Egg retrieval from encapsulated follicles in alginate hydrogels in bursa site 7 Day after transplant and their meiotic maturation in
vitro. (a) GV oocytes were retrieved from antral follicles. (b) MII oocytes were confirmed via polar body extrusion (indicated with black arrows).
(c) Egg retrieval and MII status from the bursa site. Of the 15 GV oocytes collected at Day 7 from one trial, 3 were MII after IVM (20% MII rate).
Note: MII follicles were only observed with the 1,100‐follicle condition and not for the 730‐ or 360‐follicle condition. (d) Normal spindle
morphology (indicated by an arrow) was also confirmed in MII oocytes. Image (d) depicts an oocyte obtained from an explant containing ovarian
follicles from three ovaries. Scale bar: 100 μm (a, b). DAPI, 4ʹ,6-diamidino-2-phenylindole; GV, germinal vesicle; IVM, in vitro maturation,
MII, metaphase II [Color figure can be viewed at wileyonlinelibrary.com]
MII stage oocytes, the hydrogel retrieval was challenging and reduced
the yield of follicles. The retrieval process likely contributed to the
relatively low number of retrieved follicles from the bursa relative to
the subcutaneous site. An additional advantage of subcutaneous
implantation is that follicle growth can easily be monitored via
ultrasound (Oktay et al., 2001), and human antral follicles can be
removed when they mature (typically >15mm) for oocyte collection.
Previous studies by Oktay et al. (2004) demonstrated that although a
four‐cell human embryo could be obtained from a subcutaneous
transplant of ovarian tissue, it failed to implant. To date, only two live
human births have been achieved worldwide for transplantation of
ovarian tissue at this location (Salama & Woodruff, 2015). The
transplantation of ovarian follicles, rather than ovarian tissue, may
enhance the development of the follicles to improve oocyte quality.
Murine oocytes from extracted alginate hydrogels in the subcuta-
neous site matured to MII could be fertilized and developed to the four‐
cell embryo stage. The duration of in vivo implantation (7 days) suggests
that the antral follicles developed from secondary follicles. Longer
transplantation times, approximately 3–7 weeks, are necessary for
primordial follicles to develop to the antral stage (Zheng et al., 2014).
Collectively, the primordial and primary follicles constitute the most
abundant populations in the ovarian reserve. The ability to mature these
populations for oocyte collection would ultimately provide options for
fertility preservation (Laronda et al., 2014). Future studies may explore
the use of exogenous gonadotropins to promote ovarian follicle
maturation and increase the number of oocytes retrieved for fertilization
(Drummond, 2006; Yang et al., 2006). For either ICSI or standard IVF,
40% of MII oocytes remained in MII arrest (i.e., did not progress). This
result may suggest that oocyte quality can be improved to facilitate
progression to a blastocyst stage for embryo transfer. Oocyte quality
may be improved by longer maturation periods (>7 days), or modulation
of the hydrogel (e.g., alginate and fibrin; Papavasiliou, Sokic, & Turturro,
2012; Shikanov, Smith, Xu, Woodruff, & Shea, 2011) or transplant
environment. Heterotopic sites offer advantages regarding ease of
access, yet may lack the natural cues present at orthotopic sites.
Localized delivery of exogenous growth factors, hormones, antioxidants,
or pharmacological agents [e.g., phosphatase and tensin homolog (PTEN)
inhibitors] provides a means to locally modulate the transplant
environment to improve follicle viability and oocyte output after
transplant (Demeestere et al., 2009). Gonadotropin treatment before
transplant has been shown to improve follicle survival after transplant
(Imthurn, Cox, Jenkin, Trounson, & Shaw, 2000). Such modulation may
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F IGURE 5 Fertilization competency of MII oocytes matured in a subcutaneous site is assessed via ICSI and IVF. (a) Ater ICSI, MII oocytes
progressed to the pronucleus, two‐cell, and four‐cell embryonic stages. After IVF, denuded eggs progressed to the pronucleus and two‐cell
stages. Scale bar: 100 μm. (b) After 14 MII oocytes were injected with sperm via ICSI, embryos progressed to the pronucleus (14%), two‐cell
(36%), and four‐cell (7%) stages, whereas 43% of oocytes remained in MII arrest. (c) Embryos resulting from 10 MII oocytes denuded and placed
in an IVF dish with sperm, progressed to the pronucleus (20%) and two‐cell (40%) stages, whereas 40% of oocytes remained in MII arrest.
Results obtained from two ICSI trials and one IVF trial. ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; MII, metaphase II [Color
figure can be viewed at wileyonlinelibrary.com]
enhance new blood vessel formation around the bead and can be
triggered mechanically (Demeestere et al., 2006) or through the delivery
of angiogenic factors (e.g., VEGF; Kniazeva et al., 2015; Shikanov, Zhang
et al., 2011). Gonadotropin delivery can also upregulate VEGF to induce
vessel formation (Demeestere et al., 2009). Taken together, modification
to the hydrogel or subcutaneous site may ultimately improve oocyte
quality and thus clinical outcomes.
Cryopreserved ovarian tissue from young patients with cancer can
contain tens to hundreds of thousands of follicles depending on the age
of the patient, and advances in the cryopreservation approach have
supported long‐term storage of ovarian tissue. One report has confirmed
normal tissue morphology for up to 18 years after cryopreservation
(Fabbri et al., 2016). Ovarian tissue is typically dissected into relatively
small pieces that can be more readily cryopreserved relative to large
ovarian tissue chunks. The dissection of ovarian follicles from the tissue
can be challenging, owing to the relative dense extracellular matrix of
the ovary. Dissecting the ovarian pieces results in retrieval of modest
numbers of ovarian follicles (Telfer & Zelinski, 2013), and thus the
fertility preservation strategy must efficiently support survival and
maturation given the low numbers of available follicles. The average
number of follicles transplanted herein ranged from 360 to 1,100
follicles, with the lowest number of follicles transplanted producing the
greatest efficiency for maturating to the antral stage. Additional
reductions in follicle number may be necessary for translation.
We demonstrated that the in vivo maturation strategy involving an
alginate hydrogel, which does not permit integration of host tissue with
the graft, can prevent the escape of cancer cells into vital organs, such as
the liver and lungs. The cryopreserved tissue may contain cancer cells,
such as those present within the circulation (i.e., circulating tumor cells).
In the particular case of leukemia, more than 50% of cryopreserved
ovarian tissue can contain leukemic cells (Soares et al., 2015). The
reseeding of disease has been observed clinically with ovarian tissue
transplantation (Dolmans et al., 2013). Protocols are being developed to
rid ovarian tissue of cancerous cells (Soares et al., 2015) but have not
been widely adopted for clinical use, which underscores the need to
develop technologies that prevent reseeding of cancer cells. Isolation of
transplanted follicles from host tissue has the potential to substantially
reduce the number of cancer cells in the graft (Donnez et al., 2011;
Kniazeva et al., 2015), yet follicle isolation may not be able to remove the
presence of all tumor cells in every graft. Herein, the hydrogel provided
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F IGURE 6 In vivo imaging of NSG mice before and after removal of cancer‐laden alginate hydrogels. (a) Representative image of an NSG
mouse with a subcutaneously transplanted alginate hydrogel containing 200 MDA‐MB‐231 cells expressing luciferase (imaged Day 7 after
transplant). The presence of cancer cells in the hydrogels was confirmed by the positive luminescent signal (signal detection is 600–60,000
counts). The hydrogel implant at Day 7 is denoted with a black arrow. For the control group, mice transplanted with only ovarian follicles were
imaged. Cancer cells were present only in the gel implant. (b) Mice were imaged 3 weeks after removal of hydrogels to assess the cancer cell
presence. Cancer cells were not detected in experimental mice that had cancer‐laden hydrogels removed at Day 7. Cancer cells were not detected
in negative controls as well. Three hundred and sixty ovarian follicles were also incorporated into transplanted alginate hydrogels. n = 4 per group.
MDA‐MB‐231, triple negative breast cancer cell line; NSG, non-obese diabetic-severe combined immunodeficiency (NOD-SCID) gamma
[Color figure can be viewed at wileyonlinelibrary.com]
an additional safety precaution by preventing direct contact of the host
tissue with the graft, and it did not allow the escape of the tumor cells to
colonize alternative tissues. Previous studies with the transplantation of
ovarian tissue indicated that alginate may lose integrity with the
expansion of many follicles growing and maturing simultaneously (David
et al., 2017). Herein, transplantation was performed with isolated
ovarian follicles, which did not allow the escape of cancer, yet the studies
were performed for transplant times of 7 days, which was sufficient for
the maturation of murine follicles and to confirm the feasibility of the
approach. The translation of this strategy to humans may require
substantially longer periods of time and development of alternative
materials with tunable degradation and mechanical properties to
maximize oocyte maturation and recovery.
5 | CONCLUSION
We present an alginate hydrogel as a retrievable technology to
mature ovarian follicles subcutaneously and to prevent escape and
subsequent metastasis of cancer cells. Early‐stage follicles were
transplanted within alginate hydrogels, resulting in retrieval of
antral follicles and subsequent collection of oocytes. After IVM,
MII oocytes were fertilized and progressed to the two‐cell and
four‐cell embryo stages. These findings collectively demonstrate
retrievable hydrogels as a novel approach to mature ovarian
follicles to obtain fertilizable oocytes, and also prevent direct
contact with host tissue to alleviate concerns related to reseeding
disease from cryopreserved autotransplanted ovarian tissue. This
strategy may provide a method to enhance safety and improve
oocyte quality relative to ovarian tissue transplantation with the
potential to improve clinical outcomes for female cancer patients
aiming to preserve their fertility.
ACKNOWLEDGMENTS
This work was supported by the Center for Reproductive Health
After Disease (P50HD076188) from the National Institutes of Health
National Center for Translational Research in Reproduction and
Infertility (NCTRI).
2084 | RIOS ET AL.
F IGURE 7 Absence of metastatic lesions in liver and lungs of recipient mice 3 weeks after removal of hydrogel. Representative image
of (a) liver from naïve NSG control (n = 3), (b) lung from naïve NSG control (n = 3), (c) liver from a recipient mouse with 200 cancer cells in
the hydrogel (n = 4), and (d) lung from a recipient mouse with 200 cancer cells in hydrogel (n = 4). Lung and liver tissue removed at 3 weeks did
not contain any cellular abnormalities or metastatic growths according to staining with H&E. Scale bar: 100 μm. H&E, hematoxylin and eosin;
NSG, non-obese diabetic-severe combined immunodeficiency (NOD-SCID) gamma [Color figure can be viewed at wileyonlinelibrary.com]
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